OrbusNeich Medical Group Holdings Limited filed its Monthly Return for the period ended 30 April 2026, reporting no changes in either authorised or issued share capital.

Authorised and Issued Share Capital • Authorised share capital stayed at 1.20 billion ordinary shares with a par value of USD 0.0005 each, amounting to USD 600,000. • Issued share count remained unchanged at 827.97 million shares. The company held no treasury shares during the month.

Public Float • Management confirmed compliance with the Main Board’s 25% minimum public-float requirement as at 30 April 2026.

Share-Based Incentive Schemes • Pre-IPO Share Option Scheme: 7.43 million options outstanding; no exercises recorded. • Post-IPO Share Option Scheme: 4.35 million options outstanding (exercise price: HKD 9.00). Of these, 2.20 million shares could be issued upon full exercise, while the plan still allows up to 76.60 million additional options to be granted. • Total outstanding options across both schemes amount to 11.78 million, representing a potential 1.42% dilution to the current issued share base if fully exercised. • No option exercises occurred in April, and the company raised no proceeds from option activity.

Other Securities Instruments • The issuer reported no warrants, convertibles, or other share-issuance agreements during the month.

Overall, OrbusNeich recorded zero share issuances, buybacks, or treasury-share movements in April 2026, maintaining capital stability while retaining modest optionality through its existing option pools.